Project Grant R44AI150060

The National Science Foundation (NSF) awarded a $550,000 Project Grant under the NSF Technology, Innovation, and Partnerships (TIP) program to the University of California, Los Angeles (UCLA) to develop a rapid, multiplexed diagnostic tool for serological testing of tick-borne diseases (TBDs). This 2-year project seeks to improve blood-based detection of TBDs, including Lyme disease, Babesia, Anaplasma, and relapsing fever, through an innovative point-of-care (POC) serological assay. The goal is...

This $436,236 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop a sensitive solid-state biosensor that targets the Borrelia burgdorferi (BB) protease as a biomarker to accurately diagnose both early- and late-stage active Lyme disease infections. The award to The Leland Stanford Junior University will fund research to create an epitaxial graphene-based biosensor that provides high...

This federal Project Grant award of $293,142 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to L2 Diagnostics LLC, a for-profit company based in Woodbridge, Connecticut. The goal of this Phase I project is to develop a rapid diagnostic test (RDT) in a lateral flow assay (LFA) format that can detect the Babesia microti parasite, which causes the tick-borne disease...

This federal Project Grant award of $1,176,645.00, granted by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the development of a highly accurate proteomic diagnostic assay to identify active Borreliosis (Lyme disease) infection with point-of-need collection technology. The grant recipient, George Mason University, will conduct this research in collaboration with a subcontract to The Johns Hopkins University, which will provide...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $461,375 to Yale University to systematically identify interactions between Lyme disease bacteria (Borrelia burgdorferi) and the extracellular, secreted, and transmembrane proteins of the tick vector Ixodes scapularis. The goal is to develop a better understanding of the critical pathogen-vector...

The Department of Defense's Defense Health Agency awarded a $1,330,054 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Regents of the University of California, San Francisco (UCSF). The grant supports the "CLINICAL VALIDATION AND IMPLEMENTATION OF A HOST-PATHOGEN-BASED DIAGNOSTIC ASSAY FOR EARLY LYME DISEASE AND OTHER TICK-BORNE INFECTIONS" project, with a performance period from July 1, 2024 to June 30, 2027. As a leading academic medical...

This Project Grant award of $509,130 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at the University of South Florida to investigate the global virulence regulatory network of the Lyme disease pathogen Borrelia burgdorferi. The key objectives are to: 1) Define the BosR regulon and characterize how BosR-regulated genes contribute to the infectious cycle of B. burgdorferi; 2) Examine the biological roles of...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $165,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tufts University School of Medicine for the development of an improved transposon mutagenesis system to enable comprehensive genetic analysis of Borrelia burgdorferi, the bacterium that causes Lyme disease. The project aims to create a high-efficiency transposon insertional mutagenesis system for B. burgdorferi to...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $999,316 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Pearl Diagnostics, Inc., a Baltimore-based small business. The grant supports the final integration and clinical testing required for FDA clearance of Pearl Diagnostics' lateral flow device (LFD) - a rapid, point-of-care urine test to diagnose invasive aspergillosis, an infection recently named a "critical" public...

This $698,349 Project Grant awarded on February 25, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of an "Integrated Multiplexed Diagnostic Assay Targeting Fusion Lipoproteins and Cardiolipin for Detection of Treponemal and Nontreponemal Antibodies in Syphilis Patients." The goal is to create a rapid, point-of-care diagnostic test that can definitively diagnose...